Ligand Pharmaceuticals (NASDAQ:LGND) received a $169.00 target price from stock analysts at HC Wainwright in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 14.23% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the stock. Deutsche Bank cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price objective on the stock. in a report on Monday, November 20th. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $165.00 price objective on the stock in a report on Thursday, October 12th. Craig Hallum restated a “buy” rating and issued a $170.00 price objective (up previously from $160.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, November 15th. Roth Capital restated a “buy” rating and issued a $158.00 price objective (up previously from $135.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, October 11th. Finally, BidaskClub upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Ligand Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $150.67.

Shares of Ligand Pharmaceuticals (LGND) opened at $147.95 on Friday. The firm has a market cap of $3,120.00, a PE ratio of 214.42, a price-to-earnings-growth ratio of 1.51 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals has a fifty-two week low of $95.08 and a fifty-two week high of $149.31.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.32. The business had revenue of $33.38 million for the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The business’s revenue was up 54.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. equities analysts expect that Ligand Pharmaceuticals will post 3.15 EPS for the current year.

In other news, Director John W. Kozarich sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $145.00, for a total transaction of $362,500.00. Following the sale, the director now owns 33,149 shares in the company, valued at $4,806,605. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Stephen L. Sabba sold 925 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total transaction of $126,956.25. Following the sale, the director now owns 26,985 shares in the company, valued at approximately $3,703,691.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,253 shares of company stock worth $2,884,507. Corporate insiders own 8.30% of the company’s stock.

Large investors have recently bought and sold shares of the company. 361 Capital LLC purchased a new stake in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $2,099,000. Janus Henderson Group PLC grew its holdings in shares of Ligand Pharmaceuticals by 26.7% during the third quarter. Janus Henderson Group PLC now owns 754,692 shares of the biotechnology company’s stock valued at $102,751,000 after buying an additional 159,201 shares during the last quarter. Round Table Services LLC purchased a new stake in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $205,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Ligand Pharmaceuticals by 15.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 127,792 shares of the biotechnology company’s stock valued at $17,399,000 after buying an additional 17,071 shares during the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of Ligand Pharmaceuticals by 48.7% during the third quarter. Prudential Financial Inc. now owns 72,150 shares of the biotechnology company’s stock valued at $9,823,000 after buying an additional 23,643 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/hc-wainwright-analysts-give-ligand-pharmaceuticals-lgnd-a-169-00-price-target/1804229.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Analyst Recommendations for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.